CBL and myeloproliferative disorder: Cancer-associated mutations affecting the E3 Ubiquitin ligase, CBL, which is required for ubiquitination and degradation of multiple RTKs, are also recurrent across HM, including the BCR-ABL-negative myeloproliferative neoplasms (MPN)2.